{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":5,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06066437\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-22T14:51:58.986Z","note":"Automated from all 15 indexed sources (May 2023 – Jan 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":16,"text":"- Whether adding ADT to neoadjuvant Lu-177 PSMA is needed before surgery\n- Whether and when ADT up-regulates PSMA expression enough to prime Lu-177 PSMA uptake\n- Whether Lu-177 PSMA is better given before ADT, in hormone-naive high-risk localized disease\n- Which tissue biomarkers from surgery can guide treatment after neoadjuvant Lu-177 PSMA","kind":"questions"},"drugs_tested":[["177Lu rhPSMA-10.1"],["177Lu rhPSMA-10.1","degarelix"]],"indication":"prostate cancer","name":"Nautilus","nct_id":"NCT06066437","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nautilus-nct06066437. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive 177Lu rhPSMA-10.1 alone.","label":"LeadIn: Treatment with 177Lu rhPSMA-10.1","type":"EXPERIMENTAL"}],"collaborators":["Blue Earth Therapeutics Ltd"],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":6,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Arm A: 177Lu rhPSMA-10.1","otherNames":[],"type":"DRUG"},{"name":"Arm B: 177Lu rhPSMA-10.1 plus Degarelix","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-03","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0","timeFrame":"through study completion; an average 1 year"},{"measure":"Efficacy will be assess by measuring the radiation dose to the tumor (dosimetries) and PSA assessment","timeFrame":"Up to 6 months"}],"references":[],"start_date":{"date":"2024-03-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","url":"https://clinicaltrials.gov/study/NCT06066437"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nautilus-nct06066437"}